Company Profile

Edesa Biotech Inc. Stock Price, News & Catalysts

Ticker:
EDSA
Exchange:
NASDAQ
Sector:
Biopharma
Location:
United States

Stock performance

2.17 USD (+5.58%)

Close

Last updated: November 19, 2026

—

Market cap

Why the stock is moving

As of Nov 19, 2026, EDSA closed up 5.58% at $2.17. No new same-company headline was identified in the current news window.

Company overview

Host-Directed Immunology Developer

Edesa Biotech is a clinical-stage biopharmaceutical company developing host-directed therapies for inflammatory and immune-mediated diseases. Its pipeline is organized around medical dermatology and respiratory medicine, with programs intended to modify disease-driving immune pathways rather than treat symptoms alone.

EB06 Vitiligo Program

EB06 is a fully human monoclonal antibody that binds CXCL10 and blocks its interaction with the CXCR3A and CXCR3B receptors. Edesa is developing the candidate as a systemic therapy for moderate-to-severe nonsegmental vitiligo, where CXCL10 is implicated in immune-cell trafficking to the skin and melanocyte loss. The ongoing randomized Phase 2 study is evaluating EB06 against placebo in up to 80 adults, with change in the Facial Vitiligo Area Scoring Index at Week 28 as the primary efficacy endpoint.

Paridiprubart Respiratory Program

Paridiprubart is a human monoclonal antibody targeting toll-like receptor 4, a regulator of innate immune signaling. The candidate is being developed for acute respiratory distress syndrome and is also being evaluated in patients with concurrent acute kidney injury. Clinical analyses have associated paridiprubart plus standard care with mortality reductions in respiratory-failure populations, supporting continued regulatory and late-stage development planning.

Daniluromer Dermatology Asset

Daniluromer, formerly EB01, is a 1.0% topical cream developed for moderate-to-severe chronic allergic contact dermatitis. The asset is Phase 3-ready and gives Edesa a second dermatology program alongside the systemic EB06 vitiligo study.

Partnership and Funding Model

Edesa uses partnerships and public-sector support to advance capital-intensive programs. Kyorin Pharmaceutical holds exclusive Japanese rights to develop and commercialize paridiprubart for ARDS, while Edesa retains rights outside Japan and supplies the product. The respiratory program has also received Canadian government funding and is being evaluated in a U.S. government-funded platform study.

Future catalysts

  • Initial enrollment at U.S. sites in the Phase 2 EB06 vitiligo study in the first quarter of 2027.
  • Topline results from the Phase 2 EB06 vitiligo study in the fourth quarter of 2027.

Recent news

    Similar stocks

    Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

    Frequently Asked Questions

    What is the current stock price of Edesa Biotech Inc. (EDSA)?

    Edesa Biotech Inc. (EDSA) most recently closed at 2.17 USD, a +5.58% move versus the previous session.

    What does Edesa Biotech Inc. do?

    Host-Directed Immunology Developer Edesa Biotech is a clinical-stage biopharmaceutical company developing host-directed therapies for inflammatory and immune-mediated diseases. Its pipeline is organized around medical dermatology and respiratory medicine, with programs intended to modify disease-driving immune pathways rather than treat symptoms alone. EB06...

    On which exchange is EDSA stock listed?

    Edesa Biotech Inc. (EDSA) is associated with NASDAQ, United States, Biopharma.

    What is Host-Directed?

    Host-Directed Immunology Developer Edesa Biotech is a clinical-stage biopharmaceutical company developing host-directed therapies for inflammatory and immune-mediated diseases.

    Which conditions is Edesa Biotech Inc. targeting with Host-Directed?

    Edesa Biotech Inc. is associated with immunology, dermatology, respiratory disease based on its company overview and current catalyst commentary.

    How does Edesa Biotech Inc. describe recent progress with Host-Directed?

    Initial enrollment at U.S. sites in the Phase 2 EB06 vitiligo study in the first quarter of 2027. Topline results from the Phase 2 EB06 vitiligo study in the fourth quarter of 2027.

    What is Immunology?

    Host-Directed Immunology Developer Edesa Biotech is a clinical-stage biopharmaceutical company developing host-directed therapies for inflammatory and immune-mediated diseases.

    What should investors watch for with Immunology?

    Initial enrollment at U.S. sites in the Phase 2 EB06 vitiligo study in the first quarter of 2027. Topline results from the Phase 2 EB06 vitiligo study in the fourth quarter of 2027.